Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer

Journal article

Peer reviewed

Luke T. Nordquist, Neal D. Shore, James J. Elist, Jamie C. Oliver, William Gannon, Amir H. Shahlaee, Steven A. Fuller and Hossein A. Ghanbari

Journal of clinical oncology, Vol.36(15_suppl), pp.e15166-e15166

05/20/2018

Metrics

1 Record Views

Title: Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer
Creators: Luke T. Nordquist - Urology Cancer Center and GU Research Network
Neal D. Shore - Carolina Urologic Research Center
James J. Elist - James J. Elist, M.D., Beverly Hills, CA
Jamie C. Oliver - Accelovance (United States)
William Gannon - CCTC, Inc., Provincetown, MA
Amir H. Shahlaee - Institute for Asthma and Allergy
Steven A. Fuller - Sensei Biotherapeutics (United States)
Hossein A. Ghanbari - Sensei Biotherapeutics (United States)
Publication Details: Journal of clinical oncology, Vol.36(15_suppl), pp.e15166-e15166
Identifiers: 991006262310702656
Academic Unit: Radiology
Language: English
Resource Type: Journal article